Filana Therapeutics, Inc.
FLNA
$1.91
-$0.09-4.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.58% | -22.69% | |||
| Gross Profit | 2.58% | 22.69% | |||
| SG&A Expenses | -27.91% | -11.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.46% | -15.84% | |||
| Operating Income | 19.46% | 15.84% | |||
| Income Before Tax | -16.03% | 75.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.03% | 75.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.03% | 75.56% | |||
| EBIT | 19.46% | 15.84% | |||
| EBITDA | 21.69% | 15.46% | |||
| EPS Basic | -16.05% | 75.57% | |||
| Normalized Basic EPS | 20.96% | 16.39% | |||
| EPS Diluted | -16.27% | 75.68% | |||
| Normalized Diluted EPS | 20.96% | 16.39% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||